Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

British Medical Journal (Clinical research ed.)

Volumn 284, Issue 6312, 1982, Pages 295-299

  Shah, R R ^a   Oates, N S ^a   Idle, J R ^a   Smith, R L ^a   Lockhart, J D F ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Merrell Pharmaceuticals Limited ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEBRISOQUINE; DECLINAX 10; PERHEXILINE; PERHEXILINE MALEATE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANGINA PECTORIS; DRUG INTOXICATION; DRUG METABOLISM; INTOXICATION; LIVER; MAJOR CLINICAL STUDY; NEUROPATHY; ORAL DRUG ADMINISTRATION; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; THERAPY;

ADULT; AGED; ALCOHOL DRINKING; ANGINA PECTORIS; DEBRISOQUIN; FEMALE; HUMANS; ISOQUINOLINES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PERHEXILINE; PERIPHERAL NERVOUS SYSTEM DISEASES; PIPERIDINES; SMOKING;

EID: 0020075333     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.284.6312.295     Document Type: Article

References (42)

1. Armstrong ML. A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. Postgrad Med J 1973;49,suppl 3:108–11.
2. Dettori AG, Malagnino G, Fatt F, Oriani G. Perhexiline versus prenylamine. A controlled clinical trial in coronary insufficiency. Postgrad Med J 1973;49,suppl 3:113–4.
3. Cawein MJ, Lewis RE, Hudak WJ, Hoekenga MT. Clinical evaluation of perhexiline maleate in patients with angina pectoris associated with a positive coronary artery disease index. Postgrad Med J 1973;49, suppl 3:121–4.
4. Morledge J. Effects of perhexiline maleate in angina pectoris: double-blind clinical evaluation with ECG-treadmill exercise testing. Postgrad Med J 1973;49, suppl 3:64–7.
5. Sukerman M. Clinical evaluation of perhexiline maleate in the treatment of chronic cardiac arrhythmias of patients with coronary artery disease: Postgrad Med J 1973;49,suppl 3:46–52.
6. Fleckenstein-Grun G, Fleckenstein A, Byon YK, Kim KW. Mechanisms of action of calcium antagonists in the treatment of coronary disease with special reference to perhexiline maleate. In: International symposium on perhexiline maleate. Amsterdam: Excerpta Medica, 1978:1–22. (Excerpta Medica International Congress series No 424).
7. Pepine CJ, Schang SJ, Bemiller CR. Alteration of left ventricular responses to ischaemia with oral perhexiline. Postgrad Med J 1973;49, suppl 3:43–6.
8. Pilcher J, Chandrasekhar KP, Russell RJ, Boyce MJ, Peirce TH, Ikram H. Long-term assessment of perhexiline maleate in angina pectoris. Postgrad Med J 1973;49,suppl 3:115–8.
9. Gitlin N, Nellen M. Perhexiline maleate in the treatment of angina pectoris: a double-blind trial. Postgrad Med J 1973;49,suppl 3:100–4.
10. Gitlin N. Perhexiline maleate in the management of patients with angina pectoris. 5 Afr Med J 1974;48:904–6.
11. Datey KK, Bagri AK, Kelkar PN, Varma SR, Bhootra RK, Amin BM. Perhexiline maleate: a new antianginal drug. Postgrad Med J 1973; 49,suppl 3:75–8.
12. Abaza A, Cattan D, Aziza C, Pappo E. Effets de secondaires mais réversibles à la prise de perhexiline. Nouv Presse Med 1973;2:2820.
13. Laplane D, Bousser MG, Bouche P, Touboul PJ. Peripheral neuropathies caused by perhexiline maleate. In: International symposium on perhexiline maleate. Amsterdam: Excerpta Medica, 1978:89–96. (Excerpta Medica International Congress series No 424).
14. Newberne JW. Assessment of safety data from patients on short- and long-term perhexiline therapy. Postgrad Med J 1973;49,suppl 3:125–9.
15. Lewis D, Wainwright HC, Kew MC, Zwi S, Isaacson C. Liver damage associated with perhexiline maleate. Gut 1979;20:186–9.
16. Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou J. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979;76:170–7.
17. Houdent CE, Wolf LM, Corriat A. Liver during perhexiline hypoglycaemia. Lancet 1977;ii: 1028.
18. Tomlinson IW, Rosenthal FD. Proximal myopathy after perhexiline maleate treatment. Br Med J 1977;i: 1319–20.
19. Hutchinson WM, Williams J, Cawler J. Papilloedema in patients taking perhexiline maleate. Br Med J 1978;i:305.
20. Atkinson AB, McAreavey D, Trope G. Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid). Br Heart J 1980;43:490–1.
21. Wright GJ, Leeson GA, Zeiger AV, Lang JF. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 1973;49,suppl 3:8–15.
22. L'Hermitte F, Fardeau M, Chedru F, Mallecourt J. Polyneuropathy after perhexiline maleate therapy. Br Med J 1976;i:1256.
23. Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 1978;14:195–201.
24. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;ii:584–6.
25. Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J 1978;ii:65–7.
26. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. J AW Genet 1980;17:102–5.
27. Sloan TP, Idle JR, Smith RL. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther 1981;29:493–7.
28. Shah RR, Oates NS, Idle JR, Smith RL. Genetic impairment of phenformin metabolism. Lancet 1980;i:1147.
29. Ritchie JC, Sloan TP, Idle JR, Smith RL. Toxicological implications of polymorphic drug metabolism. In: Environmental chemicals, enzyme function and human disease. (Ciba Foundation Symposium 76). Amsterdam; Excerpta Medica, 1980:219–44.
30. Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980;5:528–47.
31. Weiner M, Chenkin T, Burns J J. Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. Am J Med Sci 1954;228:36–9.
32. Brodie BB, Burns JJ, Weiner M. Metabolism of drugs in subjects with Laennec's cirrhosis. Med Exp 1959;1:290–2.
33. Nelson E. Rate of metabolism of tolbutamide in test subjects with liver disease or with impaired renal function. Am J Med Sci 1964;248:657–9.
34. Oldershausen HF von, Held H, Remmer H. Der Abbau von Pentabarbital bei leberschaden. Klin Wochenschr 1970;48:565–7.
35. Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1968;i:1275–9.
36. Held H, Oldershausen HF von. Zur Pharmakokinetik von Meprobamat bei chronischen Hepatopathien und Arzneimittelsucht. Klin Wochenschr 1969;47:78–80.
37. Anonymous. Drug metabolism in disease. Lancet 1974;i:790–l.
38. Pollet S, Hauw JJ, Escourolle R, Baumann N. Peripheral-nerve lipid abnormalities in patients on perhexiline maleate. Lancet 1977;i: 1258.
39. Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. Life Sci 1978;22:979–84.
40. Idle JR, Oates NS, Shah RR, Smith RL. Is there a genetic predisposition to phenformin-induced lactic acidosis? Br J Clin Pharmacol 1981;11:418P–9P.
41. Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation. Lancet 1981;i:837–8.
42. Bertilsson L, Mellström B, Sjöqvist F, Märtensson B, Äsberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications. Lancet 1981;i:561–2.